WallStSmart

EXACT Sciences Corporation (EXAS)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EXACT Sciences Corporation generates 3% more annual revenue ($3.25B vs $3.17B). WAT leads profitability with a 20.3% profit margin vs -6.4%. WAT earns a higher WallStSmart Score of 60/100 (C).

EXAS

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.3
Piotroski: 4/9Altman Z: 0.01

WAT

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 9.0Value: 7.3Quality: 6.8
Piotroski: 4/9Altman Z: 4.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EXAS.

WATSignificantly Overvalued (-349.9%)

Margin of Safety

-349.9%

Fair Value

$73.17

Current Price

$302.32

$229.15 premium

UndervaluedFair: $73.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EXAS1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
23.1%8/10

Revenue surging 23.1% year-over-year

WAT4 strengths · Avg: 9.5/10
Operating MarginProfitability
33.8%10/10

Strong operational efficiency at 33.8%

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
29.3%9/10

Every $100 of equity generates 29 in profit

Profit MarginProfitability
20.3%9/10

Keeps 20 of every $100 in revenue as profit

Areas to Watch

EXAS4 concerns · Avg: 3.0/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-8.7%2/10

ROE of -8.7% — below average capital efficiency

Altman Z-ScoreHealth
0.012/10

Distress zone — elevated risk

WAT2 concerns · Avg: 3.0/10
P/E RatioValuation
28.1x4/10

Moderate valuation

EPS GrowthGrowth
-3.1%2/10

Earnings declined 3.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : EXAS

The strongest argument for EXAS centers on Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.

Bull Case : WAT

The strongest argument for WAT centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 20.3% and operating margin at 33.8%. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bear Case : EXAS

The primary concerns for EXAS are Price/Book, EPS Growth, Return on Equity.

Bear Case : WAT

The primary concerns for WAT are P/E Ratio, EPS Growth.

Key Dynamics to Monitor

EXAS profiles as a growth stock while WAT is a mature play — different risk/reward profiles.

EXAS carries more volatility with a beta of 1.44 — expect wider price swings.

EXAS is growing revenue faster at 23.1% — sustainability is the question.

WAT generates stronger free cash flow (126M), providing more financial flexibility.

Bottom Line

WAT scores higher overall (60/100 vs 32/100), backed by strong 20.3% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EXACT Sciences Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?